The Reply - 16/08/18
Doi : 10.1016/j.amjmed.2018.04.003
Larry A. Weinrauch, MD a, b, c, d, John A. D'Elia, MD b, c, d, Matthew R. Weir, MD e, Suphamai Bunnapradist, MD f, Peter V. Finn, MD a, Jiankang Liu, MD, PhD a, Brian Claggett, PhD a, Anthony P. Monaco, MD c, d, g
a Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass
b Kidney and Hypertension Section, Joslin Diabetes Center, Boston, Mass
c Departments of Medicine andSurgery,Beth Israel Deaconess Medical Center, Boston, Mass
d Harvard Medical School, Boston, Mass
e Division of Nephrology, Departmentof Medicine, University of Maryland School of Medicine, Baltimore
f Division of Nephrology, Departmentof Medicine, University of Californiaat Los Angeles, Los Angeles
g Division of Nephrology, New EnglandMedical Center, Tufts UniversitySchool of Medicine, Boston,Mass
Le texte complet de cet article est disponible en PDF.
| Funding: None |
|
| Conflict of Interest: None |
|
| Authorship: Each of the authors has fully participated and has approved the final manuscript. Each author has reviewed and is responsible for the content. |
© 2018
Publié par Elsevier Masson SAS.
Vol 131 - N° 8
P. e349-e351 - août 2018 Retour au numéro
Article précédent
- New Onset Diabetes After Transplant: Data from the Folic Acid for Vascular Outcome Reduction in Transplantation Trial
- Amisha Wallia, Mark E. Molitch
- Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education
- Khadijah Breathett, Scott Maffett, Randi E. Foraker, Rod Sturdivant, Kristina Moon, Ayesha Hasan, Veronica Franco, Sakima Smith, Brent C. Lampert, Sitaramesh Emani, Garrie Haas, Rami Kahwash, Ray E. Hershberger, Philip F. Binkley, Laura Helmkamp, Kathryn Colborn, Pamela N. Peterson, Nancy Sweitzer, William T. Abraham
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?